The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
Open accessAbstract
BACKGROUND: Hydroxychloroquine and chloroquine have been proposed as treatments for coronavirus disease 2019 (Covid-19) on the basis of in vitro activity and data from uncontrolled studies and small, randomized trials. METHODS: In this randomized, controlled, open-label platform trial comparing a range of possible treatments with usual care in patients hospitalized with Covid-19, we randomly assigned 1561 patients to receive hydroxychloroquine and 3155 to receive usual care. The primary outcome was 28-day mortality. RESULTS: The enrollment of patients in the hydroxychloroquine group was closed on June 5, 2020, after an interim analysis determined that there was a lack of efficacy. Death within 28 days occurred in 421 patients (27.0%) in the hydroxychloroquine group and in 790 (25.0%) in the usual-care group (rate ratio, 1.09; 95% confidence interval [CI], 0.97 to 1.23; P = 0.15). Consistent results were seen in all prespecified subgroups of patients. The results suggest that patients in the hydroxychloroquine group were less likely to be discharged from the hospital alive within 28 days than those in the usual-care group (59.6% vs. 62.9%; rate ratio, 0.90; 95% CI, 0.83 to 0.98). Among the patients who were not undergoing mechanical ventilation at baseline, those in the hydroxychloroquine group had a higher frequency of invasive mechanical ventilation or death (30.7% vs. 26.9%; risk ratio, 1.14; 95% CI, 1.03 to 1.27). There was a small numerical excess of cardiac deaths (0.4 percentage points) but no difference in the incidence of new major cardiac arrhythmia among the patients who received hydroxychloroquine. CONCLUSIONS: Among patients hospitalized with Covid-19, those who received hydroxychloroquine did not have a lower incidence of death at 28 days than those who received usual care. (Funded by UK Research and Innovation and National Institute for Health Research and others; RECOVERY ISRCTN number, ISRCTN50189673; ClinicalTrials.gov number, NCT04381936.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288
RetractedA novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05991-x · Cited by 4,898
Estimates of the severity of coronavirus disease 2019: a model-based analysis
Verity, R., Okell, L. C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., Cuomo-Dannenburg, G., Thompson, H., Walker, P. G. T., Fu, H., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30243-7 · Cited by 3,660
Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., et al. (2020) · BMJ · doi:10.1136/bmj.m1985 · Cited by 3,481
Self-citationYao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa237 · Cited by 2,662
Gao, J., Tian, Z., & Yang, X. (2020) · BioScience Trends · doi:10.5582/bst.2020.01047 · Cited by 2,590
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Vincent, M. J., Bergeron, E., Benjannet, S., Erickson, B. R., Rollin, P. E., Ksiazek, T. G., Seidah, N. G., & Nichol, S. T. (2005) · Virology Journal · doi:10.1186/1743-422x-2-69 · Cited by 1,811
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
Geleris, J., Sun, Y., Platt, J., Zucker, J., Baldwin, M., Hripcsak, G., Labella, A., Manson, D. K., Kubin, C., Barr, R. G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2012410 · Cited by 1,625
Tang, W., Cao, Z., Han, M., Wang, Z., Chen, J., Sun, W., Wu, Y., Xiao, W., Liu, S., Chen, E., et al. (2020) · BMJ · doi:10.1136/bmj.m1849 · Cited by 1,135
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
Cavalcanti, A. B., Zampieri, F. G., Rosa, R. G., Azevedo, L. C. P., Veiga, V. C., Avezum, A., Damiani, L. P., Marcadenti, A., Kawano-Dourado, L., Lisboa, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2019014 · Cited by 1,083
Borba, M. G. S., Val, F. F. A., Sampaio, V. S., Alexandre, M. A. A., Melo, G. C., Brito, M., Mourão, M. P. G., Brito-Sousa, J. D., Baía-da-Silva, D., Guerra, M. V. F., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.8857 · Cited by 1,038
Knight, S. R., Ho, A., Pius, R., Buchan, I., Carson, G., Drake, T. M., Dunning, J., Fairfield, C. J., Gamble, C., Green, C. A., et al. (2020) · BMJ · doi:10.1136/bmj.m3339 · Cited by 1,029
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
Chen, Z., Hu, J., Zhang, Z., Jiang, S., Han, S., Yan, D., Zhuang, R., Hu, B., & Zhang, Z. (2020) · medRxiv · doi:10.1101/2020.03.22.20040758 · Cited by 847
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Sevestre, J., Mailhe, M., Doudier, B., Aubry, C., Amrane, S., et al. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101663 · Cited by 765
Molina, J. M., Delaugerre, C., Le Goff, J., Mela-Lima, B., Ponscarme, D., Goldwirt, L., & de Castro, N. (2020) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2020.03.006 · Cited by 749
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
Chen, J., Liu, D., Liu, L., Liu, P., Xu, Q., Xia, L., Ling, Y., Huang, D. F., Song, S., Zhang, D., et al. (2020) · PubMed · doi:10.3785/j.issn.1008-9292.2020.03.03 · Cited by 664
In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
Keyaerts, E., Vijgen, L., Maes, P., Neyts, J., & Ranst, M. V. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.08.085 · Cited by 649
Mahévas, M., Tran, V.-T., Roumier, M., Chabrol, A., Paule, R., Guillaud, C., Fois, E., Lepeule, R., Szwebel, T.-A., Lescure, F.-X., et al. (2020) · BMJ · doi:10.1136/bmj.m1844 · Cited by 566
Cao, J., Tu, W.-J., Cheng, W., Yu, L., Liu, Y.-K., Hu, X., & Liu, Q. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa243 · Cited by 495
Million, M., Lagier, J.-C., Gautret, P., Colson, P., Fournier, P.-E., Amrane, S., Hocquart, M., Mailhe, M., Esteves-Vieira, V., Doudier, B., et al. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101738 · Cited by 469
Armstrong, R. A., Kane, A. D., & Cook, T. M. (2020) · Anaesthesia · doi:10.1111/anae.15201 · Cited by 431
Abate, S. M., Ahmed Ali, S., Mantfardo, B., & Basu, B. (2020) · PLOS ONE · doi:10.1371/journal.pone.0235653 · Cited by 293
Treating COVID-19 with Chloroquine
Huang, M., Tang, T., Pang, P., Li, M., Ma, R., Lu, J., Shu, J., You, Y., Chen, B., Liang, J., et al. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa014 · Cited by 251
Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19
Yu, B., Li, C., Chen, P., Zhou, N., Wang, L., Li, J., Jiang, H., & Wang, D.-W. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1732-2 · Cited by 161
Dagens, A., Sigfrid, L., Cai, E., Lipworth, S., Cheng, V., Harris, E., Bannister, P., Rigby, I., & Horby, P. (2020) · BMJ · doi:10.1136/bmj.m1936 · Cited by 156
White, N. J., Watson, J. A., Hoglund, R. M., Chan, X. H. S., Cheah, P. Y., & Tärning, J. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003252 · Cited by 131
Fantini, J., Chahinian, H., & Yahi, N. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106020 · Cited by 119
Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence
Lenzer, J. (2020) · BMJ · doi:10.1136/bmj.m1335 · Cited by 114
Population Pharmacokinetics of Hydroxychloroquine in Patients With Rheumatoid Arthritis
Carmichael, S., Charles, B. G., & Tett, S. E. (2003) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200312000-00005 · Cited by 104
Rodrigo, C., Fernando, S. D., & Rajapakse, S. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.05.016 · Cited by 54
Concentration-dependent mortality of chloroquine in overdose
Watson, J. A., Tärning, J., Hoglund, R. M., Baud, F. J., Mégarbane, B., Clemessy, J. L., & White, N. J. (2020) · eLife · doi:10.7554/elife.58631 · Cited by 32
Evaluation of Potential Therapeutic Options for COVID‐19
Austin, D. J., & Okour, M. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1669 · Cited by 2
Cited by
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
WHO Solidarity Trial Consortium (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2023184 · Cited by 2,745
Abani, O., Abbas, A., Abbas, F., Abbas, M., Abbasi, S., Abbass, H., Abbott, A., Abdallah, N., Abdelaziz, A., Abdelfattah, M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00676-0 · Cited by 1,983
Berlin, D. A., Gulick, R. M., & Martinez, F. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmcp2009575 · Cited by 1,439
RECOVERY Collaborative Group (2021) · White Rose Research Online (University of Leeds, The University of Sheffield, University of York) · doi:10.17863/cam.70428 · Cited by 1,067
Lamers, M. M., & Haagmans, B. L. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00713-0 · Cited by 983
Metadata
- Authors
- The RECOVERY Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-11-19
- Volume
- 383
- Issue
- 21
- Pages
- 2030-2040
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3091868035
- Cited by
- 1,265
- References
- 38
- FWCI
- 33.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.